Skip to content
Mountain Group Partners
  • About
    • Our Firm
    • Team
  • Focus
  • Portfolio
  • News
  • Investor Login

Author: Natalie Dillard

PhaseBio reports full results of phase 2b trial of bentracimab to reverse ticagrelor’s antiplatelet activity

PhaseBio reports full results of phase 2b trial of bentracimab to reverse ticagrelor’s antiplatelet activity

read more 04/04/22
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

read more 03/28/22
AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering

AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering

read more 03/25/22
Silicon Ranch Raises $775 Million in Equity Funding Led by Manulife Investment Management

Silicon Ranch Raises $775 Million in Equity Funding Led by Manulife Investment Management

read more 01/06/22
Mountain Group Partners

3835 Cleghorn Ave | Suite 300 | Nashville, TN 37215

P: 615.843.9100615.843.9100 E: contact@mtngp.com

© Copyright 2026 Mountain Group Partners. Finely Crafted by Proof Branding.